TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
NCT00261404 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2011-05-12
Summary
Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who have cancer which is not considered curable by surgery will receive intratumoral injections of TNFerade™ plus radiation as a 4-week treatment, followed by a 3 year follow-up period.
Conditions
Interventions
- DRUG
-
TNFerade™
Sponsors & Collaborators
-
GenVec
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
NCT02557321 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
NCT00623402 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NCT00963664 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
NCT01320085 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
NCT03842943 ·Status: RECRUITING ·Phase: PHASE2
-
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 ·Status: COMPLETED ·Phase: PHASE2
-
Taxoprexin Treatment for Advanced Skin Melanoma
NCT00249262 ·Status: COMPLETED ·Phase: PHASE2
-
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
NCT03620019 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation and Combination Immunotherapy for Melanoma
NCT03850691 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
NCT00942162 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
NCT03297463 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
NCT04904120 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
NCT02816021 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
NCT04581382 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT04356729 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
NCT04207086 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma
NCT04663126 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
NCT02659540 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
NCT02723006 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
NCT02211131 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
NCT01864538 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
NCT00116363 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
NCT04526730 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
NCT00001296 ·Status: COMPLETED ·Phase: PHASE3